Department of Neurology (A.L.), Penn State University, Hershey, PA.
Division of Epidemiology, Department of Public Health Sciences (A.L., P.S.), Penn State University, Hershey, PA.
Stroke. 2020 Sep;51(9):2715-2723. doi: 10.1161/STROKEAHA.119.028899. Epub 2020 Aug 10.
We performed a systematic review and meta-analysis to assess the incidence and risk of seizures following acute stroke reperfusion therapy (intravenous thrombolysis [IVT] with r-tPA [recombinant tissue-type plasminogen activator], mechanical thrombectomy or both).
We searched major databases (MEDLINE, SCOPUS, and Cochrane Library) for articles published between 1995 and October 28, 2019. The primary outcome was the overall and treatment specific pooled incidence of poststroke seizures (PSS) following acute reperfusion therapy. We also computed the pooled incidence of early poststroke seizures and late poststroke seizures separately for all studies. We derived the risk of PSS associated with IVT in the pooled cohort of patients who received only IVT. The small number of studies (<3) that reported on the risk of PSS associated with mechanical thrombectomy alone or in combination with IVT did not allow us to compute an estimate of the risk of seizures associated with this therapy.
We identified 13 753 patients with stroke, of which 592 had seizures. The pooled incidence of PSS was 5.9 % (95% CI, 4.2%-8.2%). PSS incidence rates among patients with stroke treated with IVT, mechanical thrombectomy, and both were respectively 6.1% (95% CI, 3.6%-10.2%), 5.9% (95% CI, 4.1%-8.4%), and 5.8 % (95% CI, 3.0%-10.9%). The incidence of late PSS was 6.7% (95% CI, 4.01%-11.02%) and that of early PSS was 3.14% (95% CI, 2.05%-4.76%). The pooled odds ratio for the association between IVT and PSS was 1.24 (95% CI, 0.75-2.05).
The findings of this meta-analysis suggest that about one in 15 ischemic stroke patients treated with IVT, mechanical thrombectomy, or both develop seizures independently of the specific reperfusion treatment that they received.
我们进行了一项系统评价和荟萃分析,以评估急性卒中再灌注治疗(静脉溶栓[rtPA]、机械取栓或两者联合)后癫痫发作的发生率和风险。
我们检索了 1995 年至 2019 年 10 月 28 日期间的主要数据库(MEDLINE、SCOPUS 和 Cochrane 图书馆)。主要结局是急性再灌注治疗后卒中后癫痫发作(PSS)的总体和治疗特异性汇总发生率。我们还分别计算了所有研究中早期和晚期 PSS 的汇总发生率。我们从仅接受静脉溶栓的患者的汇总队列中得出了与 IVT 相关的 PSS 风险。只有少数研究(<3 项)报告了与机械取栓单独或联合 IVT 相关的 PSS 风险,因此我们无法计算与这种治疗相关的癫痫发作风险。
我们确定了 13753 名卒中患者,其中 592 名发生了癫痫发作。PSS 的总发生率为 5.9%(95%CI,4.2%-8.2%)。接受 IVT、机械取栓和联合治疗的卒中患者的 PSS 发生率分别为 6.1%(95%CI,3.6%-10.2%)、5.9%(95%CI,4.1%-8.4%)和 5.8%(95%CI,3.0%-10.9%)。晚期 PSS 的发生率为 6.7%(95%CI,4.01%-11.02%),早期 PSS 的发生率为 3.14%(95%CI,2.05%-4.76%)。IVT 与 PSS 之间关联的汇总优势比为 1.24(95%CI,0.75-2.05)。
这项荟萃分析的结果表明,接受 IVT、机械取栓或两者联合治疗的缺血性卒中患者中,约有 15 分之一会发生癫痫发作,与他们接受的具体再灌注治疗无关。